TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

TAVR patients with moderate or greater TR may face increased risks
When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.
Late-breaking clinical trials announced for New York Valves 2025
The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.
Next-day discharge after TAVR is still safe when alternative access is required
Even TAVR patients not treated using transfemoral access can typically go home the very next day.
Q&A: Cardiologist and EARLY TAVR co-author questions study’s execution
The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public.
Balloon-expandable, self-expanding TAVR valves associated with comparable long-term outcomes
Patients treated with the Sapien 3 platform from Edwards Lifesciences and the Evolut platform from Medtronic were linked to more similarities than differences after six years. This was a single-center study, researchers noted, but it does provide an in-depth look at the safety and effectiveness of TAVR.

heart data research doctor cardiologist AI

TAVR patients with moderate or greater TR may face increased risks

When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.

Statue of Liberty New York City healthcare

Late-breaking clinical trials announced for New York Valves 2025

The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.

Next-day discharge after TAVR is still safe when alternative access is required

Even TAVR patients not treated using transfemoral access can typically go home the very next day.

Q&A: Cardiologist and EARLY TAVR co-author questions study’s execution

The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public.

cardiologists heart doctors heart research heart data

Balloon-expandable, self-expanding TAVR valves associated with comparable long-term outcomes

Patients treated with the Sapien 3 platform from Edwards Lifesciences and the Evolut platform from Medtronic were linked to more similarities than differences after six years. This was a single-center study, researchers noted, but it does provide an in-depth look at the safety and effectiveness of TAVR.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

TAVR specialists come together to explore new data, patient selection and much more

Care teams have a lot to consider when choosing the right treatment for patients with severe aortic stenosis. Two cardiologists and a veteran cardiothoracic surgeon are taking part in a new webinar focused on that very topic.

Vinay Badhwar, MD, and his team perform a robotic TAVR explant and aortic valve replacement. Image courtesy of WVU Medicine.

Heart surgeons perform world’s first robotic TAVR explant and aortic valve replacement

The patient, 67, presented with a failing TAVR valve and a leaky mitral valve. She had undergone TAVR four years prior, but premature structural valve degeneration made a full replacement necessary. Surgeons ultimately removed the TAVR valve in addition to replacing her aortic and mitral valves—all with the help of advanced robotics.

Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement

Researchers in Italy tracked data from more than 7,000 patients who underwent AVR between the ages of 65 and 80. TAVR was associated with a significantly higher long-term risk of mortality.

Around the web

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.